Port cities have a natural advantage for clinical trials: cold-chain logistics f...
Africa Trials
3,515
US Trials
159,433
Gap Ratio
45x
Nations
54
Key Finding
Africa hosts 23,873 trials across 54 nations with extreme geographic concentration.
Regional Comparison
Distribution Analysis
Inequality Profile
Temporal & Structural
Why It Matters
Port cities have a natural advantage for clinical trials: cold-chain logistics for biologics, international airport access for monitors, and the cosmopolitan healthcare infrastructure that colonial-era investment concentrated on the coast.
The Evidence 133 words · target 156
In the spatial mapping of African clinical research, does the pattern of port city advantage reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the odds ratio of trial participation as the primary estimand using registry metadata for each nation. Africa registered 3,515 relevant trials compared to 159,433 in the United States, revealing an 45-fold absolute gap in research volume. Temporal analysis showed 17.1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted. These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape. Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.
Sentence Structure
Question
In the spatial mapping of African clinical research, does the pattern of port city advantage reveal structural inequity in African research investment?
Dataset
This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.
Method
gov through April 2026.
Primary Result
Investigators computed the odds ratio of trial participation as the primary estimand using registry metadata for each nation.
Robustness
Africa registered 3,515 relevant trials compared to 159,433 in the United States, revealing an 45-fold absolute gap in research volume.
Interpretation
Temporal analysis showed 17.
Boundary
1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted.
Extra
These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape.
Extra
Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.